Valeo Pharma Inc. (C:VPH)
Business Focus: Pharmaceuticals (NEC)
Apr 09, 2024 07:00 am ET
VALEO PHARMA TO PRESENT AT THE 2024 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE
MONTREAL, April 9, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Steve Saviuk, Valeo's Chief Executive Officer, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.
Mar 22, 2024 07:00 am ET
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. AL MOGHADDAM TO BOARD OF DIRECTORS
MONTREAL, March 22, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has joined the Company's Board of Directors.
Mar 14, 2024 05:29 pm ET
VALEO PHARMA REPORTS FIRST QUARTER 2024 RESULTS
Q1-24 revenues of $13.5 million, up 3% over Q1-23 Q1-24 adjusted EBITDA loss of $2.1 million compared to $2.2 million for Q1-23, down 6% Total Enerzair and Atectura prescriptions for the 12 months ending January 31, 2024, exceeded 78,000, up 130% over the 12 months ending January 31, 2023MONTREAL, March 14, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2024.
Mar 07, 2024 06:00 am ET
VALEO PHARMA TO HOST FIRST QUARTER 2024 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, March 7, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2024 on Thursday March 14, 2024 after market close. The Company will host a conference call to discuss those results and highlights on Friday March 15, 2024 at 8.30am (ET).
Feb 13, 2024 06:00 am ET
VALEO PHARMA ANNOUNCES BOARD OF DIRECTORS CHANGES
MONTREAL, Feb. 13, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Messrs. Robert Raich and Charles Bisaillon have joined the Company's Board of Directors and that Messrs. Michel Trudeau, Stuart Fowler, Didier Leconte and Ms. Tamara Close have all resigned from its Board of Directors.
Feb 02, 2024 04:03 pm ET
VALEO PHARMA AMENDS AGREEMENT WITH NOVARTIS PHARMACEUTICALS CANADA FOR (Pr)XIIDRA® IN CANADA AND CREDIT FACILITY WITH SAGARD HEALTHCARE ROYALTY PARTNERS, LP
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Jan 29, 2024 04:48 pm ET
VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL YEAR 2023
Record revenues of $54 million for fiscal 2023, up 94% over 2022Revenues of $13.1 million for Q4-23, up 4% over Q4-22Record annual adjusted gross profit of $16.9 million for 2023, compared to $9.4 million for 2022, up 80% 2023 adjusted EBITDA loss of $10.9 million compared to $14.5 million for 2022, down 25% Total Enerzair and Atectura prescriptions for the 12 months ending October 31, 2023, exceeded 67,000, up 179% over October 31, 2022MONTREAL, Jan. 29, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today r
Jan 22, 2024 06:00 am ET
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2023 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, Jan. 22, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2023 on Monday January 29, 2024 after market close. The Company will host a conference call to discuss those results and highlights on Tuesday January 30, 2024 at 8.30am (ET).
Nov 21, 2023 05:41 am ET
Valeo Pharma announces new chief financial officer along with $2 million in cost reductions
Valeo Pharma CEO Steve Saviuk joined Steve
Darling from Proactive to share details about recent executive changes
within the company.
Nov 20, 2023 06:00 am ET
VALEO PHARMA ANNOUNCES ORGANIZATIONAL CHANGES AND COST REDUCTION INITIATIVES
Costs reduction initiatives and organizational realignment expected to generate annual savings exceeding $2 million.MONTREAL, Nov. 20, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has undertaken a series of initiatives to reduce operating costs and drive operational efficiency as it moves toward profitability.
Nov 07, 2023 06:15 am ET
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. RICHARD LAJOIE TO BOARD OF DIRECTORS
MONTREAL, Nov. 7, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Mr. Richard Lajoie has joined the Company's Board of Directors and that Ms. Maureen C. Brennan has retired from its Board of Directors
Oct 07, 2023 01:45 am ET
CORRECT AND REPLACE: Valeo Pharma CEO credits Enerzair for strong position on Canadaâs top-growing companies list
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF)
CEO Steve Saviuk joined Proactive's Stephen Gunnion to discuss the
company's strong position on the Globe and Mail's Report on
Business annual list of Canada’s top-growing companies.
Oct 06, 2023 09:36 am ET
Valeo Pharma CEO credits Enerzair for strong position on Canadaâs top-growing companies list
Valeo
Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined
Proactive's Stephen Gunnion to discuss the company's strong
position on the Globe and Mail's Report on Business annual list of
Canada’s top-growing companies.
Oct 04, 2023 07:00 am ET
VALEO PHARMA MAKES THE LIST OF THE GLOBE AND MAIL'S FIFTH-ANNUAL RANKING OF CANADA'S TOP GROWING COMPANIES
MONTREAL, Oct. 4, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, is pleased to announce it placed No. 151 on the 2023 Report on Business ranking of Canada's Top Growing Companies.
Sep 27, 2023 11:48 am ET
Valeo Pharma secures $5M credit facility agreement with Accord Financial
Valeo Pharma CEO Steve Saviuk joined Steve
Darling from Proactive to share details the company has entered into a
credit facility agreement with Accord Financial for a total of $5
million.
Sep 27, 2023 07:00 am ET
VALEO PHARMA ENTERS INTO $5 MILLION CREDIT FACILITY AGREEMENT WITH ACCORD FINANCIAL INC.
MONTREAL, Sept. 27, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has entered into a credit facility agreement with Accord Financial Inc.
Sep 15, 2023 11:03 am ET
Valeo Pharma hits 7th straight consecutive quarter of revenue growth
Valeo Pharma CEO Steve Saviuk joined
Proactive's Steve Darling to share news regarding the
company's strong third-quarter performance.
Sep 13, 2023 07:44 pm ET
VALEO PHARMA REPORTS RECORD THIRD QUARTER 2023 REVENUES
Seventh consecutive quarter of revenue growth at $14.1 million in Q3-23, up 132% over Q3-22.Physicians prescribing Enerzair and Atectura reached 2,503 at the end of Q3-23, representing a 23% increase from the prior quarter and a 221% rise year-over-year Total Enerzair and Atectura prescriptions for the 12 months ending July 31, 2023 exceeded 56,000, up 310% over July 31, 2022$4.5 million financing completed with Investissement Québec and insiders each investing $2.0 millionMONTREAL, Sept. 13, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Ca
Sep 07, 2023 07:00 am ET
VALEO PHARMA TO HOST THIRD QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, Sept. 7, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2023 on Wednesday September 13, 2023 after market close. The Company will host a conference call to discuss those results and highlights on Thursday September 14, 2023 at 8.30am (ET).
Aug 31, 2023 06:10 pm ET
VALEO PHARMA CLOSES $4.5 MILLION FINANCING
$3.92 million raised from non-brokered private placement offering, and $0.58 million from insider loanInvestissement Québec and insiders each invest $2.0 millionProceeds from the financing to be used to strengthen working capital and support ongoing growthMONTREAL, Aug. 31, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the closing of a $4.5 million financing. The Company closed a non-brokered private placement offering (the "Offering") of 13,999,997 units (the "Units") of the Company at a pric
Jul 04, 2023 07:30 am ET
VALEO PHARMA PROVIDES UPDATE ON OPHTHALMOLOGY BUSINESS UNIT
Novartis agrees to sell global rights to XIIDRA® and several other ophthalmology products to Baucsh + LombSIMBRINZA® not included in the divestiture MONTREAL, July 4, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, notes from the news release issued by Novartis on June 30, 2023 that Novartis has agreed to sell XIIDRA®, a prescription eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease, as well as several other ophthalmology products to Bausch + Lomb Corporation. SIMBRINZA®
Jun 22, 2023 07:00 am ET
VALEO PHARMA ANNOUNCES NEW BOARD APPOINTMENTS
MONTREAL, June 22, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Ms. Tamara Close and Mr. Didier Leconte have joined its Board of Directors. Following the appointment of Ms. Close and Mr. Leconte, Valeo's Board of Directors is now comprised of 8 Directors, 5 of whom are independent.
Jun 14, 2023 11:35 am ET
Valeo Pharma 2Q results showing 6th consecutive quarter of revenue growth
Valeo Pharma CEO Steve Saviuk joined Steve
Darling from Proactive to share news the company has once again seen
record numbers as it unveils its second-quarter financials. The
numbers include the 6th consecutive quarter of revenue growth at $13.6
million, up 184% over 2Q 2022.
Jun 13, 2023 06:33 pm ET
VALEO PHARMA REPORTS RECORD SECOND QUARTER REVENUES
Sixth consecutive quarter of revenue growth at $13.6 million in Q2-23, up 184% over Q2-22.Sixth consecutive quarter of adjusted EBITDA loss reduction at $1.7 million, a 53% improvement over Q2-22, and down 24% compared to Q1-23Physicians prescribing Enerzair and Atectura reached 2,036 at the end of Q2-23, representing 29% growth from the prior quarter and a 355% increase year-over-year Total prescriptions for the 12 months ending April 30, 2023 exceeded 45,000, up 654% over April 30, 2022MONTREAL, June 13, 2023 /CNW/ - Valeo Pharma Inc. (TSX:VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Co
Jun 07, 2023 07:00 am ET
VALEO PHARMA TO HOST SECOND QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, June 7, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2023 on Tuesday June 13, 2023 after market close. The Company will host a conference call to discuss those results and highlights on Wednesday June 14, 2023 at 8.30am (ET).
May 29, 2023 10:57 am ET
Valeo Pharma 2Q results show same form as 1Q with guidance revealing record quarterly revenue
Valeo Pharma CEO Steve Saviuk joined Steve
Darling from Proactive to share guidance for the company’s
second-quarter that reveal it is heading for the sixth straight
quarter of record revenue.
May 25, 2023 07:00 am ET
VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023
Q2-23 revenues to exceed $13.5 millionQ2-23 adjusted EBITDA loss to decrease below $2.0 millionQ2-23 operating expenses to remain in line with prior quartersENERZAIR® and ATECTURA® quarterly revenues grow 270% over prior yearMONTREAL, May 25, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today provided a financial and commercial update ahead of its second quarter 2023 results.
Apr 28, 2023 07:43 am ET
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS
MONTREAL, April 28, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the proposals submitted to shareholders at its annual meeting of shareholders held on April 27, 2023 (the "Meeting").
Apr 19, 2023 07:00 am ET
VALEO PHARMA TO PRESENT AT THE 2023 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE
MONTREAL, April 19, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that Steve Saviuk, Valeo's Chief Executive Officer, will present a corporate overview and provide a commercial update on key products of the Company at the 2023 Bloom Burton & Co Healthcare Investor Conference.
Mar 17, 2023 09:40 am ET
Valeo Pharma sees record quarterly revenue with a triple-digit increase over 1Q 2022
Valeo Pharma CEO Steve Saviuk joined
Steve Darling from Proactive to share news the company had a record
quarter in the three months to January 31, 2023, with revenue of $13.2
million, up 210% over 1Q 2022.
Mar 15, 2023 05:00 pm ET
VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023
Fifth consecutive quarter of revenue growth at $13.2 million in Q1-23, up 210% over Q1-22Fifth consecutive quarter of adjusted gross profit increase at $4.2 million, up 178% over Q1-22Fifth consecutive quarter of adjusted EBITDA loss reduction at $2.2 million, a 51% improvement over Q1-22Physicians prescribing Enerzair and Atectura reached 1,583 at the end of Q1-23, representing 39% growth from the prior quarter and a 799% increase year-over-yearTotal annual Enerzair and Atectura prescriptions reached 34,000 at the end of Q1-23, up 41% sequentially and 1917% year-over-year.MONTREAL, March 15
Mar 10, 2023 08:35 am ET
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum held on March 9th are now available for online viewing. REGISTER NOW AT:...
Mar 09, 2023 06:00 am ET
VALEO PHARMA TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, March 9, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2023 on Wednesday March 15, 2023 after market close. The Company will host a conference call to discuss those results and highlights on Thursday March 16, 2023 at 8.30am (ET).
Mar 07, 2023 08:35 am ET
Life Sciences Virtual Investor Forum Agenda Announced for March 9th
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum to be held March 9th. Individual investors, institutional investors, advisors, and analysts...
Mar 06, 2023 08:35 am ET
Valeo Pharma to Webcast Live at VirtualInvestorConferences.com March 9th
Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Steve Saviuk, CEO, will present live at the Life Science Investor Forum, hosted by...
Feb 09, 2023 12:03 pm ET
Valeo Pharma announces its Onstryv product receives public reimbursement in Quebec
Valeo Pharma CEO Steve Saviuk joined
Steve Darling from Proactive to share news the company has obtained
public reimbursement from the Quebec Government for its product
Onstryv (safinamide).
Feb 07, 2023 06:00 am ET
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ONSTRYV® IN QUEBEC
Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson's patients in QuebecMONTREAL, Feb. 7, 2023 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Onstryv® (safinamide) for the treatment of patients suffering from Parkinson's disease, is now listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Quebec Régie de l'assurance maladie du Québec ("RAMQ"), effective February 1, 2023.
Feb 01, 2023 10:11 am ET
Valeo Pharma's 4Q and fiscal 2022 financials reveal record revenue
Valeo Pharma CEO Steve Saviuk joined
Steve Darling from Proactive to share news the company has released
its financial results for the fourth quarter and year-ended October
31, 2022.
Jan 30, 2023 03:50 pm ET
VALEO PHARMA REPORTS RECORD QUARTERLY AND ANNUAL REVENUES FOR THE FOURTH QUARTER AND THE FISCAL YEAR 2022
Record quarterly revenues of $12.7 million in Q4-22, up 274% over Q4-21Record revenues in 2022 of $27.7 million, up 105% over 2021Record revenues forecasted in Q1-23Creation of Ophthalmology Business Unit following the addition of XIIDRA® and SIMBRINZA®, expansion of Respiratory Business Unit to include allergy following the addition of ALLERJECT®In excess of $60 million raised in financings in 2022MONTREAL, Jan. 30, 2023 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a fast-growing Canadian pharmaceutical company, today reported its financi
Jan 30, 2023 09:59 am ET
Jan 26, 2023 06:00 am ET
VALEO PHARMA ANNOUNCES FILING OF A NEW DRUG SUBMISSION-COVID 19 WITH HEALTH CANADA FOR SABIZABULIN FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS
In the final analysis of the Phase 3 cinical study conducted by Veru Inc., sabizabulin showed a 51.6% reduction in deaths compared to placebo in hospitalized adult patients with moderate to severe COVID-19 who are at high risk for ARDSSabizabulin also showed a significant reduction of days in ICU, days on mechanical ventilation and days in the hospital
Jan 25, 2023 08:38 am ET
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2022 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, Jan. 25, 2023 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2022 on Monday January 30, 2023 after market close. The Company will host a conference call to discuss those results and highlights on Tuesday January 31, 2023 at 8.30am (ET).
Nov 21, 2022 04:13 pm ET
VALEO PHARMA ANNOUNCES SENIOR MANAGEMENT CHANGE
Valeo's President and Chief Operating Officer steps down and will continue as special advisor and member of the Board of DirectorsMONTREAL, Nov. 21, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Mr. Frederic Fasano has stepped down as Valeo's President and Chief Operating Officer. Mr. Fasano will continue to act as special advisor to the Company and will remain on the Board of Directors. Mr. Fasano's duties and responsibilities are being integrated and assumed by the Company's CEO
Nov 15, 2022 06:00 am ET
VALEO PHARMA RAISES Q4 AND FULL YEAR 2022 REVENUE GUIDANCE
Q4-2022 revenue guidance raised to a record $12.5M - $13.0MFiscal 2022 revenue guidance increased to a record $27.5M - $28.0MMONTREAL, Nov. 15, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company") a Canadian pharmaceutical company, today announced that it has raised revenue guidance for its fourth quarter of 2022 to $12.5 - $13.0 million, an increase of 14% to 18% over previously issued guidance of $11 million. The Company is also increasing its fiscal 2022 revenue guidance to $27.5 – 28.0 million, a forecasted increase exceeding 100% compared
Sep 14, 2022 07:00 am ET
VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
In a Phase 3 cinical study interim analysis, sabizabulin showed a 55.2% reduction in deaths compared to placebo in hospitalized adult patients with moderate-severe COVID-19 who are at high risk for ARDSSabizabulin also showed significant reduction of days in ICU, days on mechanical ventilation and days in the hospitalVeru submitted a request for emergency use authorization to FDA in June 2022Veru plans to request that Health Canada utliize the NDS-CV (a prioritized, COVID specific review and authorization submission) through the ACCESS Consortium regulatory pathwayMONTREAL, Sept. 14, 2022 /C
Sep 14, 2022 07:00 am ET
VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
In a Phase 3 cinical study interim analysis, sabizabulin showed a 55.2% reduction in deaths compared to placebo in hospitalized adult patients with moderate-severe COVID-19 who are at high risk for ARDSSabizabulin also showed significant reduction of days in ICU, days on mechanical ventilation and days in the hospitalVeru submitted a request for emergency use authorization to FDA in June 2022Veru plans to request that Health Canada utliize the NDS-CV (a prioritized, COVID specific review and authorization submission) through the ACCESS Consortium regulatory pathwayMONTREAL, Sept. 14, 2022 /P
Sep 13, 2022 05:14 pm ET
VALEO PHARMA REPORTS RECORD THIRD QUARTER 2022 RESULTS AND HIGHLIGHTS
Record revenues of $6.1 million in Q3-22, a 27% increase over Q2-22Record Gross Margins of $2.2 million in Q3-22, up 34% over Q2-22Record YTD-22 revenues of $15.1 million, up 48% over YTD 2021Q4-22 projected revenues to exceed $11 millionXIIDRA®, SIMBRINZA® and ALLERJECT® to boost revenues starting Q4-22Non-dilutive US $30 million financing from Sagard Healthcare Partners to accelerate growthMONTREAL, Sept. 13, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the
Sep 12, 2022 12:13 pm ET
IIROC Trading Halt - VPH.WT.A
TORONTO, Sept. 12, 2022 /CNW/ - The following issues have been halted by IIROC:
Sep 09, 2022 07:00 am ET
VALEO PHARMA TO HOST THIRD QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, Sept. 9, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2022 on Tuesday September 13, 2022 after market close. The Company will host a conference call to discuss those results and highlights on Wednesday September 14, 2022 at 8.30am (ET).
Aug 30, 2022 07:00 am ET
VALEO PHARMA ADDS PHARMACEUTICAL INDUSTRY VETERAN KYLE STEIGER TO LEADERSHIP TEAM
Kyle Steiger appointed Senior Vice-President and Chief Commercial OfficerJean-François Fournier appointed new Business Unit Head - OphthalmologyMONTREAL, Aug. 30, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the appointment of Mr. Kyle Steiger to the role of Senior Vice-President and Chief Commercial Officer ("CCO").
Aug 02, 2022 08:30 am ET
VALEO PHARMA CLOSES US$40 MILLION NON-DILUTIVE FINANCING FROM SAGARD HEALTHCARE PARTNERS
Proceeds to fund acquisition of Canadian rights to 3 growing commercial stage drugsAcquisition allows Valeo to expand into Ophthalmology and Allergy Licensing transactions to more than double Valeo's annual revenuesProvides financial flexibility to accelerate growth and reach profitability MONTREAL, Aug. 2, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a growing Canadian pharmaceutical company, is pleased to announce that, it has closed a non-dilutive US$40 million Secured Term Loan (the "Facility") from Sagard Healthcare Pa
Aug 02, 2022 07:45 am ET
VALEO PHARMA ENTERS INTO LICENSE AGREEMENT WITH KALÉO FOR THE CANADIAN RIGHTS TO ALLERJECT®
700,000 Canadians suffering from severe allergiesCanadian epinephrine auto-injector market exceeds $80M annuallyALLERJECT peak sales potential expected to exceed $25M annuallyMONTREAL, Aug. 2, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a growing Canadian pharmaceutical company, announced today that it has entered into a License, Supply, and Commercialization agreement with Kaléo Inc. for the Canadian rights to ALLERJECT, (epinephrine injection, USP) auto-injector for the treatment of serious allergic reactions.
Aug 02, 2022 07:00 am ET
VALEO PHARMA ENTERS INTO AN AGREEMENT FOR OPHTHALMIC PRODUCTS, PrXIIDRA® AND PrSIMBRINZA®, IN CANADA
Ophthalmology becomes additional strategic therapeutic areaSignificant market opportunities with more than 6 million1 Canadians suffering from dry eye disease and 400,0002 Canadians suffering from open-angle glaucoma or ocular hypertensionValeo to start recognizing revenues from XIIDRA® and SIMBRINZA® in Q4-22 MONTREAL, Aug. 2, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has entered into a Commercialization and Supply Agreement (the "Agreement") with Novartis Pharmaceuticals
Jun 14, 2022 05:55 pm ET
VALEO PHARMA REPORTS ITS SECOND QUARTER 2022 RESULTS AND HIGHLIGHTS
Q2-22 revenues of $4.8 million, up 80% over Q2-21Q2-22 gross margins of $1.7 million, up 134% over Q2-21Canadian provincial public reimbursement now complete for Enerzair® Breezhaler® and Atectura® Breezhaler® with the addition of British Columbia and NewfoundlandTSX listing of common shares and warrantsEnerzair and Atectura demonstrating fast market penetration against established asthma brandsMONTREAL, June 14, 2022 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the secon
Jun 08, 2022 07:00 am ET
VALEO PHARMA TO HOST SECOND QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, June 8, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2022 on Tuesday June 14, 2022 after market close. The Company will host a conference call to discuss those results and highlights on Wednesday June 15, 2022 at 8.30am (ET).
May 09, 2022 11:00 am ET
Valeo Pharma Inc. Opens the Market
TORONTO, May 9, 2022 /CNW/ - Steve Saviuk, Chief Executive Officer, Frederic Fasano, President and Chief Operating Officer, Luc Mainville, Senior Vice-President and Chief Financial Officer, Valeo Pharma Inc. ("Valeo" or the "Company") (TSX: VPH) and their team joined Daniel Lubienietzky, Manager, Life Sciences, Toronto Stock Exchange, to celebrate the Company's new listing on Toronto Stock Exchange and open the market.
Apr 28, 2022 08:51 am ET
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS, APPOINTMENTS AND OPTIONS AND RSU GRANTS
MONTREAL, April 28, 2022 /CNW/ - Valeo Pharma Inc. (TSX:VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announces the results of the proposals submitted to shareholders at its annual meeting of shareholders held on April 27, 2022 (the "Meeting").
Apr 25, 2022 07:00 am ET
VALEO PHARMA TO PRESENT AT THE 2022 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE
MONTREAL, April 25, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that Steve Saviuk, Valeo's Chief Executive Officer, will present a corporate overview and provide a commercial update on key products of the Company at the 2022 Bloom Burton & Co Healthcare Investor Conference.
Apr 19, 2022 07:00 am ET
VALEO PHARMA ANNOUNCES LISTING OF CONVERTIBLE DEBENTURES ON TSX
MONTREAL, April 19, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, is pleased to announce that the 12% Convertible Unsecured Subordinated Debentures (the "Debentures") issued pursuant to the $15.0 million bought deal private placement closed on December 9, 2021, have been approved for listing on the TSX under the symbol "VPH.DB" and will begin trading on Tuesday April 19, 2022.
Mar 28, 2022 07:00 am ET
VALEO PHARMA ANNOUNCES LISTING TO THE TORONTO STOCK EXCHANGE
The Company's shares and warrants to start trading on March 29th, 2022 MONTREAL, March 28, 2022 /CNW Telbec/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has received final approval for the listing of its common shares and warrants on the Toronto Stock Exchange ("TSX").
Mar 25, 2022 11:28 am ET
CSE Bulletin: Delist - Valeo Pharma Inc. (VPH, VPH.WT, VPH.WT.A)
Toronto, Ontario--(Newsfile Corp. - le 25 mars/March 2022) - At the request of the company the common shares and warrants of Valeo Pharma Inc. will be delisted at market close on March 28, 2022.
Mar 24, 2022 05:41 pm ET
VALEO PHARMA REPORTS ITS FIRST QUARTER 2022 RESULTS AND HIGHLIGHTS
Q1-22 revenues of $4.2 million, up 128% over Q1-21Q1-22 gross margins of $1.4 million, up 266% over Q1-21Public reimbursement secured in key provinces for Enerzair, Atectura and Redesca$25.0 million convertible debenture financing completedMONTREAL, March 24, 2022 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2022.
Mar 22, 2022 07:00 am ET
VALEO PHARMA SECURES ADDITIONAL PUBLIC REIMBURSEMENT FOR REDESCA™, ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER®
Canadian provincial public reimbursement now complete for Redesca with the addition of British ColumbiaEnerzair Breezhaler and Atectura Breezhaler reimbursement also secured for Saskatchewan and Prince Edward Island MONTREAL, March 22, 2022 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement ("PLA") with the British Columbia Minister of Health, for the listing and public reimbursement of Redesca and Redesca HP, its low molecular w
Mar 17, 2022 07:00 am ET
VALEO PHARMA TO HOST FIRST QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST AND ATTEND THE 8TH ANNUAL ALPHANORTH CAPITAL CONFERENCE
MONTREAL, March 17, 2022 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2022 on Thursday March 24, 2022 after market close. The Company will host a conference call to discuss those results and highlights on Friday March 25, 2022 at 8.30am (ET).
Feb 28, 2022 07:47 pm ET
VALEO PHARMA REPORTS RECORD ANNUAL REVENUES FOR FISCAL 2021
Record revenues in 2021 of $13.6 million, up 81% over 2020Annual Gross Margins for 2021, $4 Million, up 186% over 2020Q4-21 revenues of $3.4 million, up 53% over Q4-20Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler®, three transformational products launched during 2021, will help accelerate revenues and margins in 2022Public reimbursement secured in most provinces in Canada for Redesca, Enerzair Breezhaler and Atectura Breezhaler and all major private insurers Completion of new corporate structure to allow for significant growth over the coming years and enable accelerated growth of
Feb 24, 2022 07:34 am ET
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN ONTARIO, MANITOBA AND NEW BRUNSWICK
Atectura and Enerzair also now reimbursed by the Non-Insured Health Benefits ("NIHB") program of Indigenous Services Canada and Veteran Affairs Canada ("VAC")Public reimbursement now includes Ontario, Quebec, Alberta, Manitoba, Nova Scotia, New Brunswick, NIHB and VAC covering over 80% of the Canadian population Private insurance coverage across Canada exceeds 90%MONTREAL, Feb. 24, 2022 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, is proud to announce another major milestone for its two innovative Asthma
Feb 24, 2022 07:34 am ET
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN ONTARIO, MANITOBA AND NEW BRUNSWICK
Atectura and Enerzair also now reimbursed by the Non-Insured Health Benefits ("NIHB") program of Indigenous Services Canada and Veteran Affairs Canada ("VAC")Public reimbursement now includes Ontario, Quebec, Alberta, Manitoba, Nova Scotia, New Brunswick, NIHB and VAC covering over 80% of the Canadian population Private insurance coverage across Canada exceeds 90%MONTREAL, Feb. 24, 2022 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, is proud to announce another major milestone for its two innovative Asthma
Feb 21, 2022 06:00 am ET
VALEO PHARMA TO HOST FOURTH QUARTER AND YEAR-END 2021 RESULTS CONFERENCE CALL / WEBCAST
MONTREAL, Feb. 21, 2022 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2021 on Monday February 28, 2022 after market close. The Company will host a conference call to discuss those results and highlights on Tuesday March 1, 2022 at 8.30am (ET).
Jan 05, 2022 06:00 am ET
VALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION
Hesperco now available in approximately 300 stores under the Loblaws banners Clinical study yields encouraging results that hesperidin may help reduce COVID-19 associated symptoms MONTREAL, Jan. 5, 2022 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that Hesperco, its unique flavonoid formulation approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw's banners including Loblaws, Dominion, Zehrs, Fortinio's, Your Independent Grocer
Jan 05, 2022 06:00 am ET
VALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION
Hesperco now available in approximately 300 stores under the Loblaws banners Clinical study yields encouraging results that hesperidin may help reduce COVID-19 associated symptoms MONTREAL, Jan. 5, 2022 /CNW/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that Hesperco, its unique flavonoid formulation approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw's banners including Loblaws, Dominion, Zehrs, Fortinio's, Your Independent Grocer and Su
Dec 15, 2021 06:00 am ET
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER® IN QUEBEC AND NOVA SCOTIA
Public reimbursement now includes Alberta, Quebec and Nova Scotia, representing approximately 37% of the Canadian population. More than 90% private insurance coverage across Canada MONTREAL, Dec. 15, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, is proud to announce a major milestone for its two innovative Asthma therapies ; Atectura Breezhaler and Enerzair Breezehaler are now reimbursed by the Quebec RAMQ, and by Nova Scotia Minister of Health, effective December 15, 2021 and December 2, 2021 respec
Dec 09, 2021 01:51 pm ET
VALEO PHARMA CLOSES PREVIOUSLY ANNOUNCED UPSIZED $15 MILLION BOUGHT DEAL PRIVATE PLACEMENT AND CONCURRENT $10 MILLION PRIVATE PLACEMENT FROM INVESTISSEMENT QUEBEC
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
Nov 24, 2021 04:46 pm ET
Valeo Pharma Announces Upsize of Previously Announced Bought Deal Private Placement of Convertible Debentures to $15 Million With Concurrent $10 Million Private Placement From Investissement Quebec
Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo Pharma” or the “Company”), a Canadian pharmaceutical company, is pleased to announce that in connection with its previously announced bought deal private placement of convertible unsecured...
Nov 24, 2021 07:32 am ET
Valeo Pharma Announces $10 Million Bought Deal Private Placement of Convertible Debentures With Concurrent $10 Million Private Placement From Investissement Quebec
Valeo Pharma Inc. (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo Pharma” or the “Company”), a Canadian pharmaceutical company, today announced that it has entered into an agreement with Desjardins Capital Markets, as lead underwriter and sole...
Nov 15, 2021 07:21 am ET
Valeo Pharma Obtains Public Reimbursement for Redesca™ and Redesca Hp™ in Quebec
Public reimbursement coverage reaches 9 Provinces in Canada Canadian private health plan coverage now exceeding 90% MONTREAL, Nov. 15, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement ("PLA") with Quebec Minister of Health, for the listing and public reimbursement of Redesca and Redesca HP, its low molecular weight heparin ("LMWH") biosimilar for the prevention and treatment of thromboembolic disorders, on the Quebec RAMQ
Nov 03, 2021 07:00 am ET
Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta
First provincial public listing secured for both asthma medications Additional provincial public reimbursement coverage expected to follow soon85% private payer health plan coverage across Canada MONTREAL, Nov. 3, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement ("PLA") with Alberta Minister of Health, for the listing and public reimbursement of Enerzair Breezhaler and Atectura Breezhaler, its two innovative asthma therapi
Nov 03, 2021 07:00 am ET
Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta
First provincial public listing secured for both asthma medications Additional provincial public reimbursement coverage expected to follow soon85% private payer health plan coverage across Canada MONTREAL, Nov. 3, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has successfully entered into a Product Listing Agreement ("PLA") with Alberta Minister of Health, for the listing and public reimbursement of Enerzair Breezhaler and Atectura Breezhaler, its two innovative asthma therapi
Oct 13, 2021 07:00 am ET
/C O R R E C T I O N from Source -- Valeo Pharma inc./
In the news release, Valeo Pharma Obtains Listings for Redesca in 700 Hospitals and Healthcare Facilities Across Canada, issued 13-Oct-2021 by Valeo Pharma inc. over CNW, we are advised by the company that the headline was changed, it shoud read "Valeo Pharma Obtains Listings for Redesca from Two GPO Representing 700 Hospitals and Healthcare Facilities Across Canada" rather than "Valeo Pharma Obtains Listings for Redesca in 700 Hospitals and Healthcare Facilities Across Canada" as originally issued inadvertently. The complete, corrected release follows:
Oct 13, 2021 07:00 am ET
Valeo Pharma Obtains Listings for Redesca in 700 Hospitals and Healthcare Facilities Across Canada
2 Group Purchasing Organizations (GPO) listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products The 2 multi-year product listings commenced on October 1, 2021 The GPOs together represent more than 700 hospitals and healthcare facilities across 5 provinces including Ontario MONTREAL, Oct. 13, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has been awarded two multi-year listing agreements by two of Canada's largest Group Purchasing Organiza
Oct 13, 2021 07:00 am ET
Valeo Pharma Obtains Listings for Redesca in 700 Hospitals and Healthcare Facilities Across Canada
2 Group Purchasing Organizations (GPO) listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products The 2 multi-year product listings commenced on October 1, 2021 The GPOs together represent more than 700 hospitals and healthcare facilities across 5 provinces including Ontario MONTREAL, Oct. 13, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has been awarded two multi-year listing agreements by two of Canada's largest Group Purchasing Organiza
Oct 05, 2021 07:00 am ET
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Enerzair® Breezhaler® and Atectura® Breezhaler®
Agreement to provide framework to participating jurisdictions in support of provincial public listings and reimbursements of both drugs Private payer health plan coverage exceeds 85% across Canada Scientific community demonstrates growing interest in both products MONTREAL, Oct. 5, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent ("LOI") with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Enerzair Bree
Oct 05, 2021 07:00 am ET
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Enerzair® Breezhaler® and Atectura® Breezhaler®
Agreement to provide framework to participating jurisdictions in support of provincial public listings and reimbursements of both drugs Private payer health plan coverage exceeds 85% across Canada Scientific community demonstrates growing interest in both products MONTREAL, Oct. 5, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent ("LOI") with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Enerzair Bree
Sep 16, 2021 07:00 am ET
Valeo Pharma To Report Third Quarter 2021 Results and Hold Investors Conference Call / Webcast
MONTREAL, Sept. 16, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2021 on Wednesday September 22, 2021 after market close.
Aug 16, 2021 07:00 am ET
Valeo Pharma Reports on Launch of New Corporate Structure
Sales team expands to 65 bringing total employees to 95 National sales structure now actively deployed in support of Enerzair® Breezhaler® and Atectura® Breezhaler® Head office and warehouse facility expanded to support sales growth MONTREAL, Aug. 16, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has completed implementation of its new corporate structure and launched full commercial activities in support of Enerzair Breezhaler triple therapy and Atectura Breezhaler dual ther
Jul 13, 2021 07:00 am ET
Valeo Pharma Announces Additional Provincial Reimbursement Coverage for Redesca™ and Redesca HP™
Redesca™ and Redesca HP™ now covered for public reimbursement in 7 provinces and territories across CanadaPrivate payer health plan coverage in Canada now at 70% MONTREAL, July 13, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that Redesca™ and Redesca HP™, its low molecular weight heparin ("LMWH") biosimilar, is now covered for public reimbursement in 7 provinces and territories across the country in addition to several governmental agencies and 70% of privately insured lives in Can
Jul 13, 2021 07:00 am ET
Valeo Pharma Announces Additional Provincial Reimbursement Coverage for Redesca™ and Redesca HP™
Redesca™ and Redesca HP™ now covered for public reimbursement in 7 provinces and territories across CanadaPrivate payer health plan coverage in Canada now at 70% MONTREAL, July 13, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that Redesca™ and Redesca HP™, its low molecular weight heparin ("LMWH") biosimilar, is now covered for public reimbursement in 7 provinces and territories across the country in addition to several governmental agencies and 70% of privately insured lives in Can
Jun 29, 2021 07:54 pm ET
Valeo Pharma Reports its Second Quarter 2021 Results and Highlights
Q2-21 record revenues of $2.65 million, up 27% vs Q2-20 and up 42% over prior quarterQ3-21 revenues expected to increase by more than 50% over Q2-21Redesca launched in late Q2-21Enerzair® Breezhaler® and Atectura® Breezhaler® commercial shipments commenced following national respiratory sales force deploymentClosing of upsized $6.645 million debenture placement Closing of $11.5 million bought deal including full exercise of over-allotment MONTREAL, June 29, 2021 /CNW/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, toda
Jun 29, 2021 09:39 am ET
Valeo Pharma Closes $11.5 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Jun 23, 2021 09:04 am ET
Valeo Pharma to Report Second Quarter 2021 Results and Hold Investors Conference Call / Webcast
MONTREAL, June 23, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2021 on Tuesday June 29, 2021 after market close.
Jun 23, 2021 09:04 am ET
Valeo Pharma to Report Second Quarter 2021 Results and Hold Investors Conference Call / Webcast
MONTREAL, June 23, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2021 on Tuesday June 29, 2021 after market close.
Jun 22, 2021 07:00 am ET
Valeo Pharma Announces Commercial Launch of Enerzair® Breezhaler® and Atectura® Breezhaler®
Product shipments have commenced across Canada National respiratory sales force recruitment well advanced, field deployment on-going Private and public reimbursement coverage progressing Nelly Komari, joins Valeo as Senior Vice President Scientific & Medical Affairs MONTREAL, June 22, 2021 /CNW/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that commercialization of Enerzair Breezhaler and Atectura Breezhaler has commenced following product shipments across Canada and the initial deployment of its
Jun 22, 2021 07:00 am ET
Valeo Pharma Announces Commercial Launch of Enerzair® Breezhaler® and Atectura® Breezhaler®
Product shipments have commenced across Canada National respiratory sales force recruitment well advanced, field deployment on-going Private and public reimbursement coverage progressing Nelly Komari, joins Valeo as Senior Vice President Scientific & Medical Affairs MONTREAL, June 22, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that commercialization of Enerzair Breezhaler and Atectura Breezhaler has commenced following product shipments across Canada and the initial deployment
Jun 09, 2021 09:56 am ET
IIROC Trade Resumption - VPH
VANCOUVER, BC, June 9, 2021 /CNW/ - Trading resumes in:
Jun 08, 2021 03:52 pm ET
Valeo Pharma Announces $10.0 Million Bought-Deal Public Offering of Units
Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, is pleased to announce that it has entered into an agreement with Research Capital Corporation as the lead underwriter and sole...
Jun 08, 2021 03:45 pm ET
IIROC Trading Halt - VPH
VANCOUVER, BC, June 8, 2021 /CNW/ - The following issues have been halted by IIROC:
Jun 01, 2021 07:00 am ET
Valeo Pharma Provides Update on Private Payer Reimbursement for Enerzair® Breezhaler® and Atectura® Breezhaler®
Private payer health plan coverage in Canada for Enerzair Breezhaler and Atectura Breezhaler has reached 80% Reimbursement proceedings with publicly funded health plans ready to commence MONTREAL, June 1, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that private payer health plans currently covering 80% of privately insured lives in Canada have agreed to provide reimbursement for Enerzair Breezhaler and Atectura Breezhaler.
May 26, 2021 07:00 am ET
Valeo Pharma Projecting Record Revenues for Second Quarter 2021
Record revenues and margins expected for Q2-21 Redesca® launch beginning to impact financial performance Respiratory sales force infrastructure well advanced in support of coming Enerzair® Breezhaler® and Atectura® Breezhaler® commercial launch MONTREAL, May 26, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today provided an outlook for its second quarter ended April 30th, projecting record revenues and margins.
May 17, 2021 07:00 am ET
Valeo Pharma Joins Innovative Medecines Canada
MONTREAL, May 17, 2021 /CNW/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that Valeo has been accepted for admission into the Innovative Medicines Canada ("IMC") Association as a full member. IMC has represented Canada's innovative pharmaceutical industry since 1914, with 47 members across the spectrum of small, mid-size and large national and multi-national companies. The association plays a central advocacy role in all major issues related to the pharmaceutical industry, including price reform. and
Apr 29, 2021 07:00 am ET
Valeo Pharma Announces Voting Results of its 2021 Annual General and Special Meeting of Shareholders
MONTREAL, April 29, 2021 /CNW/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the voting results from its Annual General and Special Meeting of Shareholders ("AGM") held via audio webcast on April 28, 2021. A total of 34,440,511 common shares were voted, representing 52.57% of the votes attached to the issued and outstanding common shares of Valeo.
Apr 28, 2021 07:00 am ET
Valeo Pharma's Redesca® and Redesca HP® to Be Covered Under the Ontario Public Drug Benefit Program
Ontario represents 37% of the Canadian low molecular weight heparin market Additional provincial coverage expected to follow MONTREAL, April 28, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced that it has entered into a Product Listing Agreement ("PLA") with the Executive Officer of the Ontario Public Drug Program for the listing of Redesca® and Redesca HP®, its low molecular weight heparin ("LMWH") biosimilar, on the Ontario Drug Benefit Formulary effective April 30, 2021.
Apr 27, 2021 07:00 am ET
Valeo Pharma Upsizes And Closes $6.6 Million Non-Brokered Private Placement
Valeo insiders participation of $2.6 million MONTRÉAL, April 27, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has upsized and closed a $6.645 million non-brokered private placement of unsecured non-convertible debenture units (the "Private Placement").
Apr 15, 2021 07:00 am ET
Valeo Pharma Announces Commercial Launch of Redesca™ and Redesca HP™
Shipments have commenced across Canada National sales coverage in full deployment through a dedicated key account managers team Private and public reimbursement activities on target. MONTREAL, April 15, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has commenced commercial shipments across Canada of Redesca™ and Redesca HP™, its low molecular weight heparin ("LMWH") biosimilar.
Apr 14, 2021 07:00 am ET
Valeo Pharma Announces $4.0 Million Non-Brokered Private Placement of Non-Convertible Debentures
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
Apr 06, 2021 07:00 am ET
Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Redesca® and Redesca HP®
MONTREAL, April 6, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent ("LOI") with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca® and Redesca HP®, its low molecular weight heparin ("LMWH") biosimilar, for the prevention and treatment of thromboembolic disorders.
Mar 31, 2021 06:34 pm ET
Valeo Pharma Reports its First Quarter 2021 Results and Highlights
Valeo secured the Canadian rights to Enerzair® Breezhaler® and Atectura® Breezhaler®, two new innovative Asthma therapies Q1-21 net revenues of $1.9 million, up 11 % vs Q1-20Frederic Fasano appointed as President and Chief Operating OfficerRedesca® and Redesca HP® receive Health Canada approval, launching in Q3 Hesperco™ capsules at the core of a Montreal Heart Institute's COVID-19 study MONTREAL, March 31, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, today reported its financial results for the fir
Mar 30, 2021 12:21 pm ET
Acquisition of LSL Laboratory for Nearly $40 Million Dollars - Name Change - Consolidation - Announcement of a Concurrent Private Placement of Maximum $7 Million
ILEDOR EXPLORATION CORPORATION (ILE.H). (the “Corporation” or “Iledor”) is pleased to announce the signing of a letter of intent dated March 26, 2021, with the shareholders of LSL Laboratory Inc. (“LSL”) to acquire all of the outstanding shares and...
Mar 29, 2021 10:51 am ET
IIROC Trade Resumption - VPH
VANCOUVER, BC, March 29, 2021 /CNW/ - Trading resumes in:
Mar 29, 2021 10:41 am ET
Valeo Pharma Inc. Enters into an Agreement for Enerzair® Breezhaler® and Atectura® Breezhaler® in Canada
Valeo to commercialize Enerzair® Breezhaler® and Atectura® Breezhaler®, 2 innovative asthma therapies approved by Health CanadaPositions Valeo as one of the leading Canadian Respiratory companiesAlmost 4 million Canadians afflicted with asthma1; Canadian market for asthma medication exceeds $700M annually2 MONTREAL, March 29, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has entered into a Commercialization and Supply Agreement (the "Agreement") with Novartis Pharmaceuticals C
Mar 26, 2021 03:51 pm ET
IIROC Trading Halt - VPH
VANCOUVER, BC, March 26, 2021 /CNW/ - The following issues have been halted by IIROC:
Mar 26, 2021 02:15 pm ET
Valeo Pharma to Report First Quarter 2021 Results and Hold Investors Conference Call / Webcast
MONTREAL, March 26, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2021 on Wednesday March 31, 2021 after market close.
Feb 24, 2021 04:40 pm ET
Valeo Pharma Reports its 2020 Fourth Quarter and Year-End Results and Highlights
Q4-20 net revenues of $2.2 million, up 76 % vs Q4-19, 2020 net revenues of $7.5 million up 14% vs 2019 Hiring of Frederic Fasano as new President and COO Successfully launched 4 new products during FY-20 Redesca®, Redesca HP® and Amikacin approved by Health Canada subsequent to year-end $10.8 million raised in 2020 from bought deal offering and over-subscribed private placements Valeo's shares now trading on the US-OTCQB exchange under "VPHIF" MONTREAL, Feb. 24, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharm
Feb 19, 2021 06:00 am ET
Valeo Pharma to Report Fourth Quarter and 2020 Year-End Results and Hold Investors Conference Call / Webcast
MONTREAL, Feb. 19, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2020 on Wednesday February 24, 2021 after market close.
Feb 17, 2021 06:00 am ET
Valeo Pharma's Hesperco™ Capsules at the Core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial
Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patientsHesperidin interferes / inhibits 2 key proteins of SARS-CoV-2 necessary for entry and infection of cells, suggesting that hesperidin may disrupt the replication rate of the virus and enable infected patients to build natural immunityHesperidin's safety profile and immune-modulatory activity make it a highly promising molecule to intervene at various stages of the COVID-19 infection process
Feb 17, 2021 06:00 am ET
Valeo Pharma's Hesperco™ Capsules at the Core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial
Montreal Heart Institute study to evaluate the ability of hesperidin, the medicinal ingredient in Hesperco™ capsules, to reduce the severity of symptoms and the need for hospitalization in COVID-19 patientsHesperidin interferes / inhibits 2 key proteins of SARS-CoV-2 necessary for entry and infection of cells, suggesting that hesperidin may disrupt the replication rate of the virus and enable infected patients to build natural immunityHesperidin's safety profile and immune-modulatory activity make it a highly promising molecule to intervene at various stages of the COVID-19 infection process
Feb 03, 2021 07:45 am ET
An Aging Population is Increasing the Need for Novel Treatments
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- With the onset of a world health crisis, our seniors are at a greater risk than they were a decade ago. In addition, the growing senior population has tripled in size over the past 40 years. The elderly are at a higher risk of contracting diseases such as cancers, Parkinson's, diabetes, and arthritis, which has led to increased rates of these diseases. Fortunately, with the assistance of pharmaceutical companies, this vulnerable population can seek protection against such diseases. Pharmaceutical companies involved in products to help this aging populat
Jan 25, 2021 06:00 am ET
Valeo Pharma's Redesca™ Receives Positive Recommendation for Public Reimbursement in Quebec
MONTREAL, Jan. 25, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that it has received notice of a positive recommendation by Quebec's Institut national d'excellence en santé et en services sociaux ("INESSS") to the Health Minister for the inclusion of its Low Molecular Weight Heparin biosimilar (LMWH), Redesca™ and Redesca™ HP, on the list of medications covered by the Régie de l'assurance maladie du Québec (RAMQ) for the prevention and treatment of thromboembolic disorders.
Jan 18, 2021 06:00 am ET
Valeo Pharma Announces Major Addition to its Senior Management Team
Frederic Fasano named President and COO Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors MONTREAL, Jan. 18, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th, to augment its senior leadership team and support expansion of Valeo's commercial activities. Mr. Fasano has also been elected to the Company's Board of Directors eff
Jan 18, 2021 06:00 am ET
Valeo Pharma Announces Major Addition to its Senior Management Team
Frederic Fasano named President and COO Steve Saviuk continues as CEO and becomes Vice-Chairman of the Board of Directors MONTREAL, Jan. 18, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th, to augment its senior leadership team and support expansion of Valeo's commercial activities. Mr. Fasano has also been elected to the Company's Board of Directors eff
Jan 12, 2021 06:00 am ET
Valeo Pharma Highlights MDBriefCase Newsletter Comparing Hesperidin and Vitamin C for COVID-19
Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process Hesperidin may help against Covid-19 viral replication Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm MONTREAL, Jan. 12, 2021 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, provided comments today on a recently issued newsletter by MDBriefCase entitled "Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C". The complete newslett
Jan 12, 2021 06:00 am ET
Valeo Pharma Highlights MDBriefCase Newsletter Comparing Hesperidin and Vitamin C for COVID-19
Growing body of research suggests Hesperidin may interfere with SARS-CoV-2 infection process Hesperidin may help against Covid-19 viral replication Hesperidin is a potent antioxidant with anti-inflammatory activity that may help in controlling cytokine storm MONTREAL, Jan. 12, 2021 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, provided comments today on a recently issued newsletter by MDBriefCase entitled "Exploring Novel Therapeutic Approaches for Covid-19: Hesperidin vs Vitamin C". The complete newslett
Dec 29, 2020 06:00 am ET
Valeo Pharma Announces DTC Eligibility for the Trading of Its Shares on the US OTCQB Market
MONTREAL, Dec. 29, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo"), a Canadian pharmaceutical company, announced today that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States.
Dec 29, 2020 06:00 am ET
Valeo Pharma Announces DTC Eligibility for the Trading of Its Shares on the US OTCQB Market
MONTREAL, Dec. 29, 2020 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo"), a Canadian pharmaceutical company, announced today that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States.
Dec 09, 2020 06:00 am ET
Valeo Pharma Announces Health Canada Approval for Redesca™ and Redesca Hp™
Commercial launch to impact first half 2021 revenue $30 million forecasted annual peak sales 8 years of proven in-market safety Internationally Low molecular weight heparin increasingly used to prevent COVID-19 driven complications MONTREAL, Dec. 9, 2020 /CNW/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that Health Canada has issued a Notice of Compliance for Redesca and Redesca HP low molecular weight heparin ("LMWH") biosimilars.
Dec 09, 2020 06:00 am ET
Valeo Pharma Announces Health Canada Approval for Redesca™ and Redesca Hp™
Commercial launch to impact first half 2021 revenue $30 million forecasted annual peak sales 8 years of proven in-market safety Internationally Low molecular weight heparin increasingly used to prevent COVID-19 driven complications MONTREAL, Dec. 9, 2020 /PRNewswire/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that Health Canada has issued a Notice of Compliance for Redesca and Redesca HP low molecular weight heparin ("LMWH") biosimilars.
Nov 12, 2020 06:00 am ET
Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium
Amikacin receives Health Canada approval, commercialization to start in first half of 2021 Strong start for Ethacrynate Sodium commercialization in the U.S. Heightened commercial and scientific interest in Hesperco™ preceeds retail launch Strong fourth quarter sales growth favourably impacted by recent launches of Yondelis and Ametop MONTREAL, Nov. 12, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FRANKFURT: VP2), a Canadian pharmaceutical company, announced today that it has recently received a Notice of Compliance from Health Canada granting market authorization for Am
Nov 12, 2020 06:00 am ET
Valeo Pharma announces Amikacin approval in CANADA and U.S. launch of Ethacrynate Sodium
Amikacin receives Health Canada approval, commercialization to start in first half of 2021 Strong start for Ethacrynate Sodium commercialization in the U.S. Heightened commercial and scientific interest in Hesperco™ preceeds retail launch Strong fourth quarter sales growth favourably impacted by recent launches of Yondelis and Ametop MONTREAL, Nov. 12, 2020 /PRNewswire/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FRANKFURT: VP2), a Canadian pharmaceutical company, announced today that it has recently received a Notice of Compliance from Health Canada granting market authorization for Am
Oct 13, 2020 07:00 am ET
Valeo Pharma Announces That Hesperco™ Has Started Shipping
HespercoTM capsules online orders now shipping HespercoTM capsules retailer sales to begin early November MONTREAL, Oct. 13, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo"), a Canadian specialty pharmaceutical company, announced today that it has commenced shipping online orders of its unique flavonoid formulation, HespercoTM. HespercoTM capsules contain a powerful antioxidant that provides support for the immune system.
Oct 13, 2020 07:00 am ET
Valeo Pharma Announces That Hesperco™ Has Started Shipping
HespercoTM capsules online orders now shipping HespercoTM capsules retailer sales to begin early November MONTREAL, Oct. 13, 2020 /PRNewswire/ - Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo"), a Canadian specialty pharmaceutical company, announced today that it has commenced shipping online orders of its unique flavonoid formulation, HespercoTM. HespercoTM capsules contain a powerful antioxidant that provides support for the immune system.
Sep 29, 2020 07:16 pm ET
Valeo Pharma Reports its Third Quarter 2020 Results and Highlights
$6.9 million bought deal offering with full exercice of over-allotment option$1.7 million oversubscribed non-convertible debenture non-brokered private placement4 new products added to our commercial pipelineQ3 net revenues of $1.5 million, YTD 2020 net revenues of $5.3 million MONTREAL, Sept. 29, 2020 /CNW/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, today reported its financial results for the third quarter ended July 31, 2020.
Sep 23, 2020 11:01 am ET
Valeo Pharma Begins Trading on the U.S. OTCQB Market
MONTREAL, Sept. 23, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that the Company has qualified to trade on the OTCQB market in the United States. Valeo's shares have started trading today on the OTCQB under the symbol "VPHIF". The Company will also continue to maintain the listing of its Shares on the CSE under the symbol "VPH".
Sep 23, 2020 07:00 am ET
Valeo Pharma to Report Third Quarter 2020 Results and Hold Investors Conference Call / Webcast
MONTREAL, Sept. 23, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2020 on Tuesday September 29, 2020 after market close.
Sep 11, 2020 07:00 am ET
Valeo Pharma Warrants to Begin Trading Today on CSE Under the Symbol VPH.WT.A
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Sep 11, 2020 04:05 am ET
CSE Bulletin: New Listing - Valeo Pharma Inc. Warrants (VPH.WT.A)
Toronto, Ontario--(Newsfile Corp. - September 11, 2020) - Valeo Pharma Inc. Warrants (the "Warrants") have been approved for listing.
Sep 10, 2020 09:23 am ET
Valeo Pharma Announces Closing of Bought Deal Financing Including Exercise of Over-Allotment Option for Gross Proceeds of $6.9 Million
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Sep 03, 2020 07:00 am ET
Valeo Pharma Receives Hesperco™ Natural Product License Approval From Health Canada
HespercoTM capsules for immune system support to be commercially available by end of September 2020 HespercoTM pre-sales now available at online store MONTREAL, Sept. 3, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has received a Natural Product Licence approval from Health Canada authorizing the sale of its bioflavonoid formulation, HespercoTM, in Canada. HespercoTM capsules contain a powerful antioxidant that can be taken for immune system support.
Aug 24, 2020 06:00 am ET
Valeo Pharma Has Submitted Hesperco™ Natural Product License Application for Approval to Health Canada
HespercoTM capsules can be taken to support immune system Valeo Pharma enters into agreement with Ingenew Pharma Inc. MONTREAL, Aug. 24, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has filed for a Natural Product Licence with Health Canada for its unique bioflavonoid formulation, HespercoTM. HespercoTM capsules contain a powerful antioxidant that can be taken for immune system support.
Aug 21, 2020 11:33 am ET
Specialty Pharma, Fintech, AI, AR, Ecomm & Cleantech Transport: CEOs of “NEXT SUPER STOCKS” dynaCERT, NexTech AR, Valeo Pharma, and Weyland Tech, Update Investors on Transformational Growth Trends
Wall Street Reporter, the trusted name in financial news since 1843, is highlighting CEO comments and latest news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor “LiveChats”....
Aug 21, 2020 09:26 am ET
IIROC Trade Resumption - VPH
VANCOUVER, BC, Aug. 21, 2020 /CNW/ - Trading resumes in:
Aug 20, 2020 04:44 pm ET
IIROC Trading Halt - VPH
VANCOUVER, BC, Aug. 20, 2020 /CNW/ - The following issues have been halted by IIROC:
Aug 20, 2020 04:36 pm ET
Valeo Pharma Announces $6.0 Million Bought Deal Financing
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./
Aug 12, 2020 07:00 am ET
Valeo Pharma Commences Yondelis® Commercialization in Canada
MONTREAL, Aug. 12, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has commenced commercializing Yondelis® in Canada following the recently received Notice of Compliance from Health Canada authorizing the transfer of the commercial rights of Yondelis® to Valeo. Yondelis® (trabectedin) is a novel marine-derived antitumor agent manufactured by PharmaMar S.A., based in Madrid, Spain.
Aug 05, 2020 12:48 pm ET
Valeo Pharma Notifies Warrants Holders of Unchanged Expiry Date
MONTREAL, Aug. 5, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has no intention at this time to accelerate the expiry of the share purchase warrants of the Company (the"Warrants") issued pursuant to a short form prospectus dated July 11, 2019, each Warrant having an exercise price of $0.60 and an expiry date of July 25, 2022. All other terms of these Warrants remain unchanged, including the right of the Company to accelerate on occurrence of a subsequent acceleration event in accordance with
Jul 31, 2020 12:03 pm ET
Specialty Pharma, Telemedicine, Mobile Shopping & E-Wallets, Augmented Reality & Virtual Tradeshows. CEO’s of NEXT SUPER STOCK presenters, Weyland Tech, CloudMD, NexTech AR, and Valeo Pharma Addressin
Wall Street Reporter, the trusted name in financial news since 1843, is highlighting CEO comments and latest news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences. More than 9,200...
Jul 29, 2020 07:00 am ET
Valeo Pharma Applies for Listing on the U.S. OTCQB Market
MONTREAL, July 29, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has completed and filed its application to list the Company's Class A shares ("Shares") on the OTCQB market in the United States.
Jul 29, 2020 07:00 am ET
Valeo Pharma Applies for Listing on the U.S. OTCQB Market
MONTREAL, July 29, 2020 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has completed and filed its application to list the Company's Class A shares ("Shares") on the OTCQB market in the United States.
Jul 28, 2020 02:40 pm ET
Valeo Pharma to Present at Wall Street Reporter's Livestream Conference on July 29, 2020
MONTREAL, July 28, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it will be presenting at Wall Street Reporter's livestream conference on Wednesday July 29, 2020.
Jul 28, 2020 02:40 pm ET
Valeo Pharma to Present at Wall Street Reporter's Livestream Conference on July 29, 2020
MONTREAL, July 28, 2020 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it will be presenting at Wall Street Reporter's livestream conference on Wednesday July 29, 2020.
Jul 13, 2020 10:40 am ET
Valeo Pharma Receives Approval from Health Canada for the Transfer of Commercial Rights to Ametop™
AmetopTM commercialization to begin in July 2020First of four Valeo products scheduled for launch this summer MONTREAL, July 13, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has received a Notice of Compliance from Health Canada authorizing the transfer of the AmetopTM commercial rights to Valeo. Valeo entered into a licensing agreement with Alliance Pharma plc in April 2020 for the exclusive commercialization rights to AmetopTM in Canada.
Jul 10, 2020 03:43 pm ET
Valeo Pharma Closes $1.7 Million Oversubscribed Private Placement
Proceeds to be used to support the summer launch of four products MONTREAL, July 10, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has closed a non-brokered oversubscribed $1.7 million private placement of non-convertible debenture units (the "Private Placement").
Jul 02, 2020 07:00 am ET
Valeo Pharma Reports its 2020 Second Quarter Results and Initiates $1 Million Debenture Private Placement
Revenues of $2.1 million, up 112% compared to Q2 2019 Net loss of $0.9 million, down 25% compared to Q2 2019 EBITDA loss down 42% at $0.6 million compared to $1.1 million for Q2 2019 MONTREAL, July 2, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, today reported its financial results for the second quarter ended April 30, 2020.
Jun 08, 2020 07:00 am ET
Valeo Pharma Receives Approval from Health Canada for the Transfer of Commercial Rights to Yondelis® in Canada
Yondelis® is an important treatment option for soft tissue sarcoma Commercialization to begin summer 2020 MONTREAL, June 8, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has received a Notice of Compliance from Health Canada authorizing the transfer of the commercial rights of Yondelis® to Valeo. Yondelis® (trabectedin) is a novel marine-derived antitumor agent manufactured by PharmaMar S.A., based in Madrid, Spain.
Apr 28, 2020 07:00 am ET
Valeo Pharma Licenses Canadian Rights to Ametop™ Gel from Alliance Pharma
AmetopTM sales expected to start contributing to Valeo's revenues in the second half of 2020 MONTREAL, April 28, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has entered into a licensing agreement with Alliance Pharma plc (AIM: APH) ("Alliance") for the exclusive commercialization rights to AmetopTM Gel (Tetracaine hydrochloride gel) in Canada.
Mar 27, 2020 07:00 am ET
Valeo Pharma Reports its 2020 First Quarter Results
Revenues of $1.7 million, up 34% compared to previous quarter Net loss of $1.1 million, down 20% compared to previous quarter Positive recommendation for the inclusion of Onstryv® on the list of medications covered in Quebec MONTREAL, March 27, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, today reported its financial results for the first quarter ended January 31, 2020.
Mar 17, 2020 07:00 am ET
Valeo Pharma Comments on World Health Organization's Best Practices Recommending Use of Low Molecular Weight Heparin to Help Prevent Complications Related to COVID-19 Infections
MONTREAL, March 17, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, commented today on the World Health Organization's ("WHO") recently issued interim guidance regarding the prophylaxis use of low molecular weight heparin ("LMWH") to help prevent complications in the clinical management of severe acute respiratory infections when novel coronavirus (COVID-19) infection is suspected.
Feb 28, 2020 06:00 am ET
Valeo Pharma Reports 2019 Financial Results and Closing of $2.1 Million Private Placement
2019 revenues of $6.6 million, up 50% compared to 2018 2019 gross margin up 68% compared to 2018 Successful launch of Onstryv® for Parkinson's disease New Drug Submission Filing for Redesca, Valeo's low molecular weight heparin biosimilar MONTREAL, Feb. 28, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company today reported its financial results for the year-ended October 31, 2019.
Feb 06, 2020 06:00 am ET
Valeo Pharma's Onstryv® Receives Positive Recommendation for Public Reimbursement in Quebec
MONTREAL, Feb. 6, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has received notice of a positive recommendation by Quebec's Institut national d'excellence en santé et en services sociaux ("INESSS") to the Health Minister for the inclusion of Onstryv® on the list of medications covered by the Régie de l'assurance maladie du Québec (RAMQ).
Jan 21, 2020 06:00 am ET
Valeo Pharma Signs Licensing Agreement with Pharmamar to Commercialize Yondelis® in Canada
Deal strengthens Valeo's presence in the Canadian oncology market Yondelis® sales to start contributing to Valeo's revenues in the second half of 2020 MONTREAL, Jan. 21, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has signed a licensing agreement with PharmaMar for the exclusive rights to commercialize Yondelis® (trabectedin), a novel marine-derived antitumor agent, to ensure uninterrupted supply of this important product in Canada.
Nov 22, 2019 04:30 pm ET
CORRECTION FROM SOURCE - Valeo Pharma Announces Change of Auditor
MONTREAL, Nov. 22, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, issued the following news release to amend its news release of October 30, 2019 in connection with its change of auditor from MNP LLP (the "Former Auditor") to PricewaterhouseCoopers LLP (the "Successor Auditor").
Nov 14, 2019 05:00 am ET
Valeo Pharma Announces Filing of a New Drug Submission for Low Molecular Weight Heparin in Canada
MONTREAL, Nov. 14, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that the New Drug Submission ("NDS") filed for a low molecular weight heparin ("LMWH") biosimilar has been accepted for review by Health Canada.
Nov 06, 2019 06:00 am ET
Valeo Pharma Announces $4.0 Million Non-Brokered Private Placement of Convertible Debentures
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
Oct 30, 2019 04:00 pm ET
Valeo Pharma Announces Change of Auditor
Company also refiles its unaudited Q3-2019 interim financial statements MONTREAL, Oct. 30, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company focused on Neurodegenerative Diseases, Oncology and Hospital Specialty Products, today announced that it has changed its auditor from MNP LLP (the "Former Auditor") to PricewaterhouseCoopers LLP (the "Successor Auditor").
Sep 26, 2019 07:00 am ET
Valeo Pharma Appoints Michel Trudeau to its Board of Directors
MONTREAL, Sept. 26, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (the "Company" or "Valeo"), a Canadian specialty pharmaceutical company focused on Neurodegenerative Diseases, Oncology and Hospital Specialty Products, today announced the appointment of Mr. Michel Trudeau to its Board of Directors. The nomination is effective as of September 25, 2019.
Sep 25, 2019 07:00 am ET
Valeo Pharma reports its third quarter 2019 financial results
Record Q3-2019 revenues of $2.6 million compared to $2.1 million in Q3-2018 YTD-2019 Revenues of $5.4 million compared to $2.6 million YTD-2018 Successful launch of Onstryv® (safinamide tablets) for the treatment of patients suffering from Parkinson's Disease Acquired the Canadian rights to a low molecular weight heparin biosimilar targeting a $200M market. Closed a $3.1 million public financing. MONTREAL, Sept. 25, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (the "Company" or "Valeo"), a Canadian specialty pharmaceutical company focused on Neurodegenerative Diseases, Oncology and Hosp
Jul 29, 2019 07:00 am ET
Valeo Pharma Warrants To Begin Trading On CSE Under The Symbol VPH.WT
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
Jul 25, 2019 11:29 am ET
Valeo Pharma Announces Closing of $3.1 Million Prospectus Offering of Units and Debt Conversion of $1.0 Million
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
Jul 15, 2019 07:50 am ET
Valeo Pharma Files Final Short Form Prospectus for its Unit Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
Jul 10, 2019 11:35 am ET
Newron’s commercialization partner Zambon and Valeo Pharma announce the launch of Onstryv® (safinamide) for Parkinson’s disease in Canada
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5.XE), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, is pleased to report that its partner Zambon S.p.A. and Valeo Pharma Inc. announced today the launch of Onstryv® (safinamide) for the treatment of Parkinson’s disease in Canada.
Jul 10, 2019 07:00 am ET
Valeo Pharma Announces the Canadian Launch of Onstryv® (Safinamide Tablets) for the Treatment of Parkinson's Disease
First new oral treatment for Parkinson's Disease approved in over a decade Parkinson's Disease affects a growing number of Canadians with over 100,000 currently afflicted Total Canadian market for Parkinson's Disease drugs exceeds $100 million per year MONTREAL, July 10, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo"), a Canadian specialty pharmaceutical company, today announced the Canadian launch of Onstryv® (safinamide tablets) for the treatment of patients suffering from Parkinson's Disease. Valeo has the exclusive rights to commercialize Onstryv® in Canada under a license ag
Jul 08, 2019 07:00 am ET
Valeo Pharma Enters into a Licensing Agreement for Canadian Rights to Heparin Biosimilar
MONTREAL, July 08, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, has signed a licensing agreement with an International pharmaceutical manufacturer whereby Valeo has been granted the exclusive right to register, distribute and market a low molecular weight heparin ("LMWH") biosimilar in Canada.
Jul 03, 2019 07:00 am ET
Valeo Pharma reports its second quarter 2019 financial results
Q2-2019 Revenues of $1.0 million compared to $0.3 million in Q2-2018 H1-2019 Revenues of $2.8 million compared to $0.5 million in H1-2018 Strong pre-launch interest and product demand for Onstryv® (safinamide tablets) from all channels across Canada MONTREAL, July 3, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) (the "Company" or "Valeo"), a Canadian specialty pharmaceutical company focused on Neurodegenerative Diseases, Oncology and Hospital Specialty Products, today reported its financial results for the second quarter ended April 30, 2019.
May 27, 2019 08:15 am ET
Valeo Pharma Announces Pricing of $0.50 Per Unit and Warrant Terms for its Prospectus Offering
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES/
May 01, 2019 09:00 am ET
Valeo Pharma Announces Short Form Prospectus Unit Offering and Refiling of Its Condensed Consolidated Interim Financial Statements and Related MD&A
Valeo Pharma Inc. (CSE:VPH) (“Valeo Pharma” or the “Company”) a Canadian specialty pharmaceutical company dedicated to commercializing innovative prescription products, is pleased to announce that it has filed a preliminary short form prospectus in...
Apr 25, 2019 08:00 am ET
Valeo Pharma to Present at 2019 Bloom Burton & Co. Healthcare Investor Conference
MONTREAL, April 25, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH), a Canadian specialty pharmaceutical company dedicated to commercializing innovative prescription products, is pleased to announce that it will be presenting at the Bloom Burton & Co. Healthcare Investor Conference to be held April 30-May 1, 2019 in Toronto, Ontario.
Mar 27, 2019 07:00 am ET
Valeo Pharma Inc. Reports 2019 First Quarter Results
ONSTRYV™ and Benztropine approved by Health CanadaCompany Announces Significant Increase in Revenues and Licenses Six Additional Products for its Hospital Portfolio
Feb 28, 2019 03:05 pm ET
Valeo Pharma Inc. Reports 2018 Fourth Quarter and Year End Results
Revenues increase 243% over the prior year ONSTRYVTM approved by Health Canada in January 2019Listed on CSE in February 2019
Feb 22, 2019 09:10 am ET
CSE New Listing - Valeo Pharma Inc. Commences Trading on the Canadian Securities Exchange - Video News Alert on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - February 22, 2019) - Valeo Pharma Inc. (CSE:VPH) is one of the latest new listing on the Canadian Securities Exchange. Founded in 2003, Valeo Pharma has a long history of successfully commercializing pharmaceutical products in Canada.
Feb 20, 2019 07:00 am ET
Valeo Pharma Announces Listing of its Shares on the Canadian Securities Exchange Under the Symbol VPH
MONTREAL, Feb. 20, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo Pharma") a Canadian specialty pharmaceutical company, is pleased to announce the listing and trading of its shares on the Canadian Securities Exchange ("CSE") under the symbol "VPH". Founded in 2003, Valeo Pharma has a long history of succesfully commercializing pharmaceutical products in Canada and is therapeutically focused on neurodegenerative diseases, woman's health and oncology. With the recent approval by Health Canada of Onstryv, a novel treatment for Parkinson's disease, Valeo Pharma is preparing for the lau
Feb 20, 2019 07:00 am ET
Valeo Pharma Announces Listing of its Shares on the Canadian Securities Exchange Under the Symbol VPH
MONTREAL, Feb. 20, 2019 /PRNewswire/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo Pharma") a Canadian specialty pharmaceutical company, is pleased to announce the listing and trading of its shares on the Canadian Securities Exchange ("CSE") under the symbol "VPH". Founded in 2003, Valeo Pharma has a long history of succesfully commercializing pharmaceutical products in Canada and is therapeutically focused on neurodegenerative diseases, woman's health and oncology. With the recent approval by Health Canada of Onstryv, a novel treatment for Parkinson's disease, Valeo Pharma is preparing for the lau
Feb 19, 2019 04:13 pm ET
Valeo Pharma Completes Private Placement
MONTREAL, Feb. 19, 2019 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo Pharma" or the "Corporation") a Canadian specialty pharmaceutical company, is pleased to announce that the Corporation has closed the final tranche of its previously announced non-brokered private placement of convertible debentures (the "Offering"). Total gross proceeds raised under all tranches of this Offering was $1,400,000.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
